1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Biotest AG

Biotest AG

BIESF
Biotest AGUS flagOther OTC
32.00
USD
- -
- -
1.60BMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
12.51
13.39
14.71
13.51
10.31
9.55
10.12
10.59
12.24
13.03
13.04
17.3
- -
16.35
Basic EPS, GAAP
0.94
0.84
0.48
-2.09
-1.16
-0.1
4.58
-0.13
-0.8
-1.61
-0.81
3.21
- -
-0.63
Free Cash Flow per Basic Share
-0.02
-1.34
-1.42
-1.41
-5.34
-1.82
-2.64
-1.71
-1.1
0.4
-1.76
-0.91
- -
0.37
Dividend per Share
0.16
0.17
0.2
0.21
0.03
0.06
0.02
0.02
0.02
0.02
0.02
- -
- -
- -
Book Value per Share
6.14
6.28
6.43
4.86
3.56
3.23
6.95
6.5
5.61
4.06
3.82
7.31
- -
7.54
Tangible Book Value per Share
8.62
10.58
10.44
8.79
7.98
7.87
11.6
11.7
10.81
9.33
8.96
12.23
- -
12.7
Basic Weighted Avg Shares
35
37
40
40
40
40
40
40
40
40
40
40
- -
39
Sales/Revenue/Turnover
440
501
582
535
408
378
400
419
484
516
516
685
726
635
Operating Margin (%)
11.36
10.04
9.12
6.9
8.31
-8.81
0.62
-1.6
-0.52
-10.1
-1.65
18.89
11.8
1.72
Depreciation Expense
31
32
32
22
20
22
25
32
30
31
36
36
41
- -
Net Income, GAAP
33
32
19
-82
-46
-4
182
-5
-31
-63
-32
127
26
-24
Effective Tax Rate (%)
36.71
33.05
59.06
22.41
74.58
- -
- -
- -
- -
- -
- -
- -
43.44
323.93
Profit Margin (%)
7.59
6.39
3.3
-15.43
-11.23
-0.93
45.39
-1.12
-6.48
-12.3
-6.14
18.55
3.64
-3.86
Working Capital
202
438
550
461
321
198
370
408
451
416
489
371
649
629
LT Debt
71
226
326
336
330
287
329
402
461
490
565
382
592
- -
Total Equity
369
461
480
412
361
348
495
477
442
380
371
499
531
510
Return on Invested Capital (%)
6.46
5.7
2.86
3.63
1.18
- -
- -
- -
- -
- -
- -
- -
4.37
- -
Return on Capital (%)
13.33
8.65
4.38
-13.07
-8.02
- -
- -
- -
- -
- -
- -
- -
4.99
34.21
Return on Common Equity (%)
22.64
14.01
7.68
-37.1
-27.5
-2.91
89.98
-1.92
-13.28
-33.37
-20.58
57.64
8.75
-8.15

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
- -
6
- -
LT Borrowings
- -
538
- -
LT Finance Leases
- -
53
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
40
40
Market Capitalization
1,072
1,153
1,149

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
704
810
789
Cash, Cash Equivalents & STI
38
120
60
Accounts Receivable, Net
132
158
155
Inventories
488
480
524
Total Current Liabilities
277
160
160
Payables & Accruals
- -
- -
- -
ST Debt
- -
6
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.56%
3.42%
6.37%
Free Cash Flow
-73.22%
-190.69%
-189.2%
Net Income, GAAP
-602.04%
8.03%
-79.21%
Sales/Revenue/Turnover
3.23%
12.17%
6.08%
Total Cash Common Dividend
- -
- -
300%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
117
158
225
184
685
2024
215
157
151
204
726
2025
124
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.53
0.55
2.18
- -
3.21
2024
0.74
0.24
-0.25
- -
- -
2025
-0.55
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Jorg Schuttrumpf
Full Time Employees
2,495
Sector
Healthcare
Industry
Biotechnology
Address
Landsteinerstrasse 5 Dreieich Germany 63303
IPO Date
Jan 9, 2014
Website
biotest.com
Similar Companies
Medigen Vaccine Biologics Corporation (6547.TWO)
Day One Biopharmaceuticals, Inc. (DAWN)
Precigen, Inc. (PGEN)
Botanix Pharmaceuticals Limited (BOT.AX)
Grace Therapeutics, Inc. (GRCE)
Rhythm Pharmaceuticals, Inc. (RYTM)
Business
Biotest AG develops, manufactures and markets plasma proteins and biotherapeutic drugs derived from human blood plasma for the therapeutic areas of clinical immunology, haematology and intensive care medicine; its core products include immunoglobulins such as Intratect 5% and 10%, Yimmugo, Cytotect CP Biotest, Hepatect CP, Varitect CP and Zutectra; clotting factors such as Haemoctin SDH, Haemonine and Vihuma; and albumins and other concentrates such as Albiomin 5% and 20%, Biseco, Cofact and Pentaglobin. Founded in 1946 and headquartered in Dreieich near Frankfurt, Germany, the company operates production facilities primarily in Dreieich with a capacity expansion under the Biotest Next Level project doubling plasma processing to up to 3 million litres annually by 2026; it maintains subsidiaries in Austria, Switzerland, Hungary and the Czech Republic, over 40 plasma collection centres in Germany, Hungary and the Czech Republic, and sells products in more than 70 countries across Europe, the Middle East, Asia, Africa, North and South America through its own sales organisations, distribution partners and majority shareholder Grifols SA. Biotest, in which Grifols holds a 97.14% voting stake following its 2022 acquisition, intensified strategic collaboration with Grifols in 2023-2024 through technology transfer agreements, development services and the sale of five distribution companies in Spain, Brazil, Italy, the UK and France to leverage Grifols' global network; in 2024, Yimmugo received US FDA approval for primary immunodeficiencies and a long-term exclusive US distribution deal with Kedrion Biopharma expected to generate over USD 1 billion in revenue over seven years, while Fibrinogen completed phase III trials for acquired fibrinogen deficiency with marketing authorisation applications submitted in Germany, Austria, Spain and the US, anticipating first approvals in mid-2025; Trimodulin advances in phase III for severe community-acquired pneumonia via the ESsCAPE study; and the company expanded plasma centres and ramped up Biotest Next Level production including albumin and Fibrinogen validation.